Spun out of University of Duisburg-Essen and University of Düsseldorf, Abalos has raised funding to kickstart development of arenavirus-based immunotherapies.
Abalos Therapeutics, a Germany-based cancer immunotherapy spinout of University of Duisburg-Essen and University of Düsseldorf, launched yesterday with €12m ($13.3m) of series A capital from investors co-led by pharmaceutical firm Boehringer Ingelheim.
Venture capital fund Gründerfonds Ruhr co-led the round, which also included public-private partnership High-Tech Gründerfonds and NRW.Bank, the state development bank of North Rhine-Westphalia.
Boehringer Ingelheim invested through its corporate venturing subsidiary, Boehringer Ingelheim Venture Fund.
Abalos is developing cancer immunotherapies, leveraging its Fast Evolution…
